Creon: Pancreatic enzyme replacement therapy shortages lead to “concern and anxiety”
A continuing shortage of the pancreatic enzyme replacement therapy (PERT) medication, Creon, within the UK, is generating “deep concern and anxiety” among patients, healthcare professionals, and pharmacists, various representative groups have cautioned.
Earlier this May, the Department of Health and Social Care issued a national alert related to patient safety regarding the scarcity of Creon, a drug prescribed to manage pancreatic exocrine insufficiency in individuals suffering from conditions such as cystic fibrosis, pancreatic cancer, and pancreatitis. The department highlighted that this supply disruption stemmed from a limited availability of essential active pharmaceutical ingredients, coupled with manufacturing constraints impeding the production of quantities sufficient to meet the current demand.1
As there is no clinical substitute for those affected, both medical experts and charity organizations have raised alarms about the potential risks to the safety and wellbeing of patients.
In …
